Compare ClearPoint Neuro Inc (CLPT) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs Wendys Co — how do they compare? ClearPoint Neuro Inc trades at $14.58 (market cap $454.21M), while Wendys Co trades at $8.39 (market cap $1.44B). The key difference: Wendys Co is far larger — about 3.2× ClearPoint Neuro Inc's market cap, and Wendys Co pays a 3.71% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| CLPT | WEN | |
|---|---|---|
Market Cap | $454.21M | $1.44B |
Sector | Health | Consumer Cyclical |
52-Week High | $29.60 | $10.68 |
52-Week Low | $8.66 | $6.17 |
Enterprise Value | $488.79M | $5.17B |
Dividend Yield | — | 3.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $14.56, down slightly by 0.07% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q2 2026 revenue growth to $42 million but missed earnings estimates with a loss of $0.38 per share, reflecting ongoing investment in clinical and preclinical services. Despite negative net income margins and cash flow challenges, analyst consensus remains unanimously bullish with 3 buy ratings.
The outlook hinges on successful execution of growth initiatives in neuro drug delivery and regulatory progress with partners, though high valuation multiples and persistent losses pose significant risks. Near-term catalysts include Q3 2026 earnings and partner developments, but investors face volatility from operational cash burn and competitive pressures.
Wendy's stock (WEN) trades at $7.30, down 5.07% amid significant operational challenges. The company faces declining U.S. traffic, a 50% dividend cut, and loss of its position as America's second-largest burger chain to Burger King. Despite beating Q2 2026 EPS estimates ($0.18 vs. $0.16 expected), revenue trends remain weak with profit margins contracting from 7.58% in 2025 to 5.72% projected for 2026. Technical indicators show bearish momentum with key support at $7.00.
The outlook remains challenging as new CEO Bob Wright implements a turnaround strategy. While valuation appears reasonable (P/E 11.44, P/S 0.65), execution risks are elevated given competitive pressures and $2.66 billion debt load. Analyst sentiment is mixed with 62.75% hold ratings, reflecting uncertainty about the company's ability to regain market share and improve franchisee economics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
